Arthneeti

Albert David Share Price & Earnings Call Analysis

₹769.25+0.10% today
Market cap
₹439 Cr
P/E
19.46
ROE
-0.44%
Price to sales
1.21
Debt to equity
0.08
52W high / low
₹899 / ₹587
Sales growth (5Y)
6.20%
EBITDA margin
7.35%
Net profit margin
-0.52%
Promoter holding
62.24%
Sales (last year)
₹364 Cr

Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Albert David rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Albert David.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Albert David

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Albert David

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +81929388898998837571879086
Expenses +72797780798892828081857983
Operating Profit101316810161-5-113113
OPM %12%14%17%9%11%1%6%1%-6%-15%3%12%3%
Other Income +0181217102321-9-522-212-25
Interest0000000001110
Depreciation2212222222223
Profit before tax7292723182225-10-128-320-25
Tax %48%20%24%20%29%15%28%-8%-13%6%28%23%-15%
Net Profit +4232019131918-9-108-315-21
EPS in Rs6.5441.1635.5732.8022.6233.0131.66-16.45-18.1013.91-5.7826.81-37.55

Financials of Albert David

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +317318293285316320246313341362345334
Expenses +281286266267286289227272297315342328
Operating Profit3731271830301941444735
OPM %12%10%9%6%10%10%8%13%13%13%1%2%
Other Income +2438915717161558307
Interest321111111013
Depreciation15988788997710
Profit before tax20632618382927475197251
Tax %32%24%39%45%29%34%19%25%29%22%32%379%
Net Profit +1448161027192235367517-1
EPS in Rs24.0084.1027.9617.2446.6833.5938.7961.7863.38132.1530.14-2.61
Dividend Payout %23%7%20%32%13%21%15%15%14%9%17%-192%

Financials of Albert David

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital666666666666
Reserves87131177180205217239274306377387386
Borrowings +302030280226531230
Other Liabilities +7167717684959511610611210798
Total Liabilities193224285290295320341401423498511519
Fixed Assets +4944878377918488808399100
CWIP5595521137221
Investments16485968113122138183193273260243
Other Assets +12212713013499106119130148135151155
Total Assets193224285290295320341401423498511519

Financials of Albert David

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +28682030323037401146-28-8
Cash from Investing Activity +-9-38-36-11-19-20-37-40-5-3323-4
Cash from Financing Activity +-18-187-5-17-10-2-2-6-8012
Net Cash Flow112-1015-40-2-1-14-5-0
Free Cash Flow1862-03145153532635-43-36
CFO/OP95%303%115%204%126%149%202%129%59%131%-629%-49%

Financials of Albert David

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days474141352534292932302937
Inventory Days176187217173151148151124149126201187
Days Payable103102117127102132104969598118104
Cash Conversion Cycle12012614181745076578758112120
Working Capital Days272524102118-10-3414-136247
ROCE %18%17%15%7%18%14%12%17%17%28%6%1%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals